文献速递其他结缔组织病

内皮素受体拮抗剂与磷酸二酯酶5抑制剂治疗系统性硬化指端溃疡的临床比较

A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

主要结局为主要溃疡愈合时间,两组相当;ERA组新发指端溃疡风险显著低于PDE5i组。使用钙通道阻滞剂(CCB)的患者24周内无新发溃疡。

要点

  • ERA与PDE5i的主要溃疡愈合时间无显著差异。
  • ERA较PDE5i显著降低新发指端溃疡风险。
  • CCB背景下24周内无新发指端溃疡。

核心结论

  • ERA与PDE5i的主要溃疡愈合时间相当。
  • ERA在减少新发指端溃疡方面比PDE5i更有效。
  • CCB可能作为背景用药有效。

研究设计与样本

  • 前瞻性、多中心、观察性队列研究,纳入韩国13个医疗中心的活动性SSc相关指端溃疡患者。
  • 49例接受ERA,11例接受PDE5i(9例西地那非、1例乌地那非、1例他达拉非),3例接受其他药物。

主要发现

  • ERA组 vs PDE5i组主要溃疡愈合时间的未调整HR为0.75(95%CI 0.35, 1.64;P=0.47)。
  • 调整年龄、性别、CCB使用、指端溃疡总数和初始主要溃疡面积后,主要溃疡愈合时间HR为0.80(95%CI 0.36, 1.78;P=0.59)。
  • ERA组 vs PDE5i组新发指端溃疡的未调整HR为0.39(95%CI 0.16, 0.93;P=0.03)。
  • 调整后新发指端溃疡HR为0.32(95%CI 0.13, 0.81;P=0.02)。
  • 接受CCB的患者在24周时无新发指端溃疡。

关键数值与推荐

  • 主要结局为主要溃疡愈合时间,次要结局为新发指端溃疡时间。
  • 随访时间为治疗开始后4、8、12和24周。

临床怎么用

  • 对于活动性SSc相关指端溃疡,ERA与PDE5i在促进愈合方面疗效相当。
  • 若目标是减少新发指端溃疡,可优先考虑ERA。
  • CCB可作为背景用药考虑。

局限性

  • 为观察性队列研究,非随机对照,存在混杂可能。
  • PDE5i组样本量较小(11例),组间样本量不均衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the efficacy of an endothelin receptor antagonist (ERA) and phosphodiesterase type5 inhibitors (PDE5is) for treating SSc-related digital ulcers (DUs). METHODS: This prospective, multicentre, observational cohort study recruited patients with active SSc-related DUs from 13 medical centres in South Korea. The primary outcome was time to cardinal ulcer (CU) healing. A secondary outcome was time to new DU occurrence. Patients were followed up 4, 8, 12 and 24 weeks after treatment initiation. RESULTS: Sixty-three patients were analysed. Their mean age was 49.9 years (s.d. 11.4) and 49 were female. Twenty-eight had limited SSc. Forty-nine patients received ERA, 11 received a PDE5i (9 sildenafil, 1 udenafil and 1 tadalafil) and 3 received other medication. The hazard ratio (HR) for time to CU healing in the ERA group vs the PDE5i group was 0.75 (95% CI 0.35, 1.64; P = 0.47) in an unadjusted model and 0.80 (95% CI 0.36, 1.78; P = 0.59) in a model adjusted for age, sex, use of calcium channel blockers (CCBs), total DU number and initial CU area. The HR for new DU development in the ERA group vs the PDE5i group was 0.39 (95% CI 0.16, 0.93; P = 0.03) in an unadjusted model and 0.32 (95% CI 0.13, 0.81; P = 0.02) in an adjusted model. No patients receiving CCBs developed new DUs at 24 weeks. CONCLUSION: Time to CU healing is comparable for ERA and PDE5i. ERAs are more effective in reducing new DU occurrence than PDE5is. CCBs may be effective as a background medication.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Chang SH, Jun JB, Lee YJ, et al. A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis. Rheumatology (Oxford). 2021. PMID: 33576774. doi:10.1093/rheumatology/keab147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。